Compounding Explained: 503A vs 503B, Shortage Rules, and the Semaglutide Salts Problem

Drug compounding is the practice of creating customized pharmaceutical preparations to meet specific patient needs that cannot be met by commercially available, FDA-approved products. This can include altering a drug's dosage form (for example, turning a tablet into a liquid for a patient who cannot swallow pills), adjusting the strength, removing allergens, or combining multiple medications into a single preparation.

Compounding has a long history in pharmacy practice and serves a legitimate medical purpose. However, compounded drugs are not FDA-approved, which means they have not undergone the same rigorous testing for safety, efficacy, and manufacturing quality as commercially manufactured drugs. The legal framework for compounding is governed primarily by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, each of which establishes different requirements and oversight mechanisms.

The distinction between legitimate compounding and illegal drug manufacturing is critical. Compounding is intended to fill gaps in the commercial drug supply for individual patients or healthcare facilities. When compounding pharmacies begin producing large quantities of drugs that are essentially copies of commercially available products, they cross the line into manufacturing, which requires FDA approval and GMP compliance.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. Under 503A, a licensed pharmacist or physician may compound a drug product for an individual patient based on a valid, patient-specific prescription from a licensed prescriber. The pharmacy must be licensed by the state in which it operates and must comply with United States Pharmacopeia (USP) standards for compounding, including USP <795> for non-sterile and USP <797> for sterile preparations.

Key restrictions under 503A include: the compounded product must not be an "essentially a copy" of a commercially available drug (with certain exceptions for drugs in shortage); the pharmacy may not compound drugs that appear on the FDA's list of products that have been withdrawn or removed from the market for safety or efficacy reasons; and the pharmacy may not sell compounded drugs across state lines in quantities that exceed regulatory thresholds without additional oversight.

For patients, the 503A pathway means that a licensed physician must write a prescription specifically for them, and the compounding pharmacy fills that prescription on a patient-by-patient basis. This is the most common pathway through which patients access compounded peptide preparations. The pharmacy is inspected by state boards of pharmacy, not the FDA, though the FDA retains enforcement authority over compounding practices that violate federal law.

Section 503B, created by the Drug Quality and Security Act of 2013 in response to the 2012 New England Compounding Center meningitis outbreak, established a new category of compounding entity called an "outsourcing facility." These facilities voluntarily register with the FDA and are subject to FDA inspection under current Good Manufacturing Practice (cGMP) standards, providing a higher level of quality assurance than traditional 503A pharmacies.

Unlike 503A pharmacies, 503B facilities may compound drugs without patient-specific prescriptions, allowing them to produce larger batches for use by healthcare providers and hospitals. They must report adverse events to the FDA, comply with cGMP requirements, and include specific labeling on their products. The FDA publishes a list of registered 503B outsourcing facilities on its website, which patients and providers can check to verify a facility's registration status.

The 503B pathway offers a middle ground between traditional compounding and full pharmaceutical manufacturing. Products from registered 503B facilities carry more quality assurance than those from 503A pharmacies because of FDA inspection and cGMP compliance, but they are still not FDA-approved products. Patients and clinicians should verify that any 503B facility they use is currently registered and has a clean inspection history, which can be confirmed through the FDA's public database.

One of the most significant exceptions in compounding law involves drug shortages. When a commercially available drug is on the FDA Drug Shortage List, compounding pharmacies (both 503A and 503B) may compound versions of that drug even if it would otherwise be considered an "essentially a copy" of the commercial product. This exception exists to ensure patient access to medically necessary drugs during supply disruptions.

The drug shortage exception has been particularly relevant for GLP-1 receptor agonists like semaglutide and tirzepatide, which experienced significant supply shortages due to unprecedented demand. During these shortages, compounding pharmacies were permitted to compound versions of these drugs, creating a large market for compounded GLP-1 products. When a drug is removed from the shortage list, compounders must generally stop making copies of the commercially available product, though transition periods and legal challenges have complicated this timeline.

Patients and providers should monitor the FDA Drug Shortage Database (accessdata.fda.gov/scripts/drugshortages/) to understand the current shortage status of any peptide drug. A drug's presence on or removal from the shortage list directly affects whether compounded versions can be legally produced. This creates a dynamic regulatory landscape where the legality of a compounded peptide product can change as supply conditions evolve.

One of the most contentious issues in peptide compounding involves the salt forms of semaglutide. The FDA-approved products (Ozempic, Wegovy, Rybelsus) contain semaglutide base as the active ingredient. Many compounding pharmacies have been producing semaglutide sodium or semaglutide acetate, arguing that these salt forms are different active ingredients from semaglutide base and therefore are not "essentially copies" of the approved products.

The FDA has taken the position that semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide in FDA-approved products. This distinction has profound implications. If these salt forms are different active ingredients, they cannot be compounded as copies of the FDA-approved drug under the shortage exception. The FDA has argued that compounders using these salt forms are effectively creating unapproved new drugs rather than compounding copies of approved drugs during a shortage.

This issue is the subject of active litigation and regulatory dispute. Some compounding pharmacies and industry groups argue that the salt forms are pharmacologically equivalent and should be treated as the same active ingredient for compounding purposes. The outcome of these legal challenges will significantly affect the availability of compounded semaglutide products and may set precedent for how other peptide salt forms are treated under compounding law. Patients should be aware that compounded semaglutide products may use different salt forms than the FDA-approved versions, and the regulatory status of these products is not fully settled.

Both sections 503A and 503B prohibit compounding pharmacies from producing drugs that are "essentially a copy" of a commercially available drug product. The purpose of this restriction is to prevent compounding pharmacies from operating as unlicensed drug manufacturers, producing large quantities of products that directly compete with FDA-approved drugs without meeting the same safety and quality standards.

A compounded drug is generally considered "essentially a copy" if it is identical or nearly identical to a commercially available drug in terms of active ingredient, route of administration, dosage form, and strength. Exceptions exist when the commercially available drug is in shortage, or when a prescriber determines that a compounded product with a meaningful difference (such as a different dosage form or the removal of an allergen) is medically necessary for a specific patient.

The "essentially a copy" doctrine creates a complex landscape for compounded peptides. When a peptide drug like semaglutide is on the shortage list, compounding is broadly permitted. When the shortage ends, compounders must either stop production or demonstrate that their product has a meaningful difference from the commercial version and serves a legitimate patient-specific need. This transition period has been a source of significant regulatory and legal conflict.

Patients receiving compounded peptide preparations should verify that the pharmacy is properly licensed and, if it claims to be a 503B facility, that it is registered with the FDA. Start by checking the pharmacy's state license through the relevant state board of pharmacy. The National Association of Boards of Pharmacy (NABP) provides tools to verify pharmacy licenses at nabp.pharmacy.

For 503B outsourcing facilities, the FDA maintains a public list of registered facilities at fda.gov. Check that the facility is currently registered and review any publicly available inspection reports. The FDA also publishes warning letters and enforcement actions on its website, which can reveal quality or compliance problems at specific facilities.

Third-party verification services like LegitScript (legitscript.com) provide additional information about pharmacy legitimacy and can help identify rogue or unlicensed operators. Be cautious of any pharmacy that does not require a valid prescription, sells directly to consumers without prescriber involvement, or operates without verifiable state licensure. These are red flags that the pharmacy may not be operating within the legal compounding framework.